The DOI matches its Crossref record; 143 of the 143 references it cites were found in a registry or an index.
Cancer vaccines
Open accessAbstract
Cancer vaccines are designed to promote tumor specific immune responses, particularly cytotoxic CD8 positive T cells that are specific to tumor antigens. The earliest vaccines, which were developed in 1994-95, tested non-mutated, shared tumor associated antigens that had been shown to be immunogenic and capable of inducing clinical responses in a minority of people with late stage cancer. Technological developments in the past few years have enabled the investigation of vaccines that target mutated antigens that are patient specific. Several platforms for cancer vaccination are being tested, including peptides, proteins, antigen presenting cells, tumor cells, and viral vectors. Standard of care treatments, such as surgery and ablation, chemotherapy, and radiotherapy, can also induce antitumor immunity, thereby having cancer vaccine effects. The monitoring of patients' immune responses at baseline and after standard of care treatment is shedding light on immune biomarkers. Combination therapies are being tested in clinical trials and are likely to be the best approach to improving patient outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
Salgado, R., Denkert, C., Demaria, S., Sirtaine, N., Klauschen, F., Pruneri, G., Wienert, S., Van den Eynden, G., Baehner, F. L., Penault-Llorca, F., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu450 · Cited by 3,113
Cancer immunotherapy: moving beyond current vaccines
Rosenberg, S. A., Yang, J. C., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,972
Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells
Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., & Schadendorf, D. (1998) · Nature Medicine · doi:10.1038/nm0398-328 · Cited by 2,862
Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
Postow, M. A., Callahan, M. K., Barker, C. A., Yamada, Y., Yuan, J., Kitano, S., Mu, Z., Rasalan, T., Adamow, M., Ritter, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112824 · Cited by 2,087
Cancer immunotherapy via dendritic cells
Palucka, K., & Banchereau, J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3258 · Cited by 2,049
Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells
Hsu, F. J., Benike, C., Fagnoni, F., Liles, T. M., Czerwinski, D., Taidi, B., Engleman, E. G., & Levy, R. (1996) · Nature Medicine · doi:10.1038/nm0196-52 · Cited by 1,804
Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y.-C., Dudley, M. E., Wunderlich, J. R., Somerville, R. P., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,718
Eshhar, Z., Waks, T., Gross, G., & Schindler, D. G. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.2.720 · Cited by 1,658
Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated
Demaria, S., Ng, B., Devitt, M. L., Babb, J. S., Kawashima, N., Liebes, L., & Formenti, S. C. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.09.012 · Cited by 1,388
Cheever, M. A., Allison, J. P., Ferris, A. S., Finn, O. J., Hastings, B. M., Hecht, T. T., Mellman, I., Prindiville, S. A., Viner, J. L., Weiner, L. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0737 · Cited by 1,388
Brentjens, R. J., Rivière, I., Park, J. H., Davila, M. L., Wang, X., Stefanski, J., Taylor, C., Yeh, R., Bartido, S., Borquez-Ojeda, O., et al. (2011) · Blood · doi:10.1182/blood-2011-04-348540 · Cited by 1,286
Macrophage Polarization Comes of Age
Mantovani, Sica, & Locati, M. (2005) · Immunity · doi:10.1016/j.immuni.2005.10.001 · Cited by 1,259
Vincent, J., Mignot, G., Chalmin, F., Ladoire, S., Bruchard, M., Chevriaux, A., Martin, F., Apetoh, L., Rébé, C., & Ghiringhelli, F. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3690 · Cited by 1,245
Tumor Antigens Recognized by T Lymphocytes
Boon, T., Cerottini, J.-C., Van den Eynde, B., van der Bruggen, P., & Van Pel, A. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.002005 · Cited by 1,221
Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen
Lehmann, P. V., Forsthuber, T., Miller, A., & Sercarz, E. E. (1992) · Nature · doi:10.1038/358155a0 · Cited by 1,186
Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment
Harlin, H., Meng, Y., Peterson, A. C., Zha, Y., Tretiakova, M., Slingluff, C., McKee, M., & Gajewski, T. F. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2281 · Cited by 1,121
Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia
Kenter, G. G., Welters, M. J. P., Valentijn, A. R. P. M., Lowik, M. J. G., Berends-van der Meer, D. M. A., Vloon, A. P. G., Essahsah, F., Fathers, L. M., Offringa, R., Drijfhout, J. W., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810097 · Cited by 1,102
Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Rivoltini, L., Topalian, S. L., Miki, T., & Rosenberg, S. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.3515 · Cited by 1,092
Suzuki, E., Kapoor, V., Jassar, A. S., Kaiser, L. R., & Albelda, S. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0883 · Cited by 1,054
Frederick, D. T., Piris, A., Cogdill, A. P., Cooper, Z. A., Lezcano, C., Ferrone, C. R., Mitra, D., Boni, A., Newton, L. P., Liu, C., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1630 · Cited by 944
Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Sakaguchi, K., Appella, E., Yannelli, J. R., Adema, G. J., Miki, T., & Rosenberg, S. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.14.6458 · Cited by 914
gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma
Schwartzentruber, D. J., Lawson, D. H., Richards, J. M., Conry, R. M., Miller, D. M., Treisman, J., Gailani, F., Riley, L., Conlon, K., Pockaj, B., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1012863 · Cited by 911
Coulie, P. G., Brichard, V, Van Pel, A., Wölfel, T., Schneider, J., Traversari, C., Mattei, S., De Plaen, E., Lurquin, C., Szikora, J. P., et al. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.1.35 · Cited by 903
Ghiringhelli, F., Larmonier, N., Schmitt, E., Parcellier, A., Cathelin, D., Garrido, C., Chauffert, B., Solary, E., Bonnotte, B., & Martin, F. (2004) · European Journal of Immunology · doi:10.1002/eji.200324181 · Cited by 880
Dendritic-Cell-Based Therapeutic Cancer Vaccines
Palucka, K., & Banchereau, J. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.004 · Cited by 869
Banchereau, J., Palucka, A. K., Dhodapkar, M. V., Burkeholder, S. B., Taquet, N., Rolland, A., Taquet, S., Coquery, S., Wittkowski, K. M., Bhardwaj, N., et al. (2001) · PubMed · Cited by 806
Walter, S., Weinschenk, T., Stenzl, A., Zdrojowy, R., Pluzanska, A., Szczylik, C., Staehler, M., Brugger, W., Dietrich, P.-Y., Mendrzyk, R., et al. (2012) · Nature Medicine · doi:10.1038/nm.2883 · Cited by 788
Boni, A., Cogdill, A. P., Dang, P., Udayakumar, D., Njauw, C.-N. J., Sloss, C. M., Ferrone, C. R., Flaherty, K. T., Lawrence, D. P., Fisher, D. E., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0118 · Cited by 742
Traversari, C., van der Bruggen, P., Luescher, I. F., Lurquin, C., Chomez, P., Van Pel, A., De Plaen, E., Amar-Costesec, A., & Boon, T. (1992) · The Journal of experimental medicine · doi:10.1084/jem.176.5.1453 · Cited by 679
Immune parameters affecting the efficacy of chemotherapeutic regimens
Zitvogel, L., Kepp, O., & Kroemer, G. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.223 · Cited by 669
Antibody-modified T cells: CARs take the front seat for hematologic malignancies
Maus, M. V., Grupp, S. A., Porter, D. L., & June, C. H. (2014) · Blood · doi:10.1182/blood-2013-11-492231 · Cited by 616
Erdag, G., Schaefer, J. T., Smolkin, M. E., Deacon, D. H., Shea, S. M., Dengel, L. T., Patterson, J. W., & Slingluff, C. L. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3218 · Cited by 590
Soiffer, R., Lynch, T., Mihm, M., Jung, K., Rhuda, C., Schmollinger, J. C., Hodi, F. S., Liebster, L., Lam, P., Mentzer, S., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.22.13141 · Cited by 571
Maximizing Tumor Immunity With Fractionated Radiation
Schaue, D., Ratikan, J. A., Iwamoto, K. S., & McBride, W. H. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2011.09.049 · Cited by 567
Okada, H., Kalinski, P., Ueda, R., Hoji, A., Kohanbash, G., Donegan, T. E., Mintz, A. H., Engh, J. A., Bartlett, D. L., Brown, C. K., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.7744 · Cited by 567
Self-citationPrognostic significance of autoimmunity during treatment of melanoma with interferon
Krauze, M. T., Tarhini, A., Gogas, H., & Kirkwood, J. M. (2011) · Seminars in Immunopathology · doi:10.1007/s00281-011-0247-y · Cited by 507
Gene-engineered T cells for cancer therapy
Kershaw, M. H., Westwood, J. A., & Darcy, P. K. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3565 · Cited by 505
Adoptive T Cell Transfer for Cancer Immunotherapy in the Era of Synthetic Biology
Kalos, M., & June, C. H. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.002 · Cited by 486
Hailemichael, Y., Dai, Z., Jaffarzad, N., Ye, Y., Medina, M. A., Huang, X.-F., Dorta-Estremera, S. M., Greeley, N. R., Nitti, G., Peng, W., et al. (2013) · Nature Medicine · doi:10.1038/nm.3105 · Cited by 457
Disis, M. L., Gooley, T. A., Rinn, K., Davis, D., Piepkorn, M., Cheever, M. A., Knutson, K. L., & Schiffman, K. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.06.171 · Cited by 423
Liu, C., Peng, W., Xu, C., Lou, Y., Zhang, M., Wargo, J. A., Chen, J. Q., Li, H. S., Watowich, S. S., Yang, Y., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1626 · Cited by 381
Van Tendeloo, V. F., Van de Velde, A., Van Driessche, A., Cools, N., Anguille, S., Ladell, K., Gostick, E., Vermeulen, K., Pieters, K., Nijs, G., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008051107 · Cited by 377
Le, D. T., Brockstedt, D. G., Nir-Paz, R., Hampl, J., Mathur, S., Nemunaitis, J., Sterman, D. H., Hassan, R., Lutz, E., Moyer, B., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2121 · Cited by 369
Inhibition of dendritic cell maturation by herpes simplex virus
Salio, M., Cella, M., Suter, M., & Lanzavecchia, A. (1999) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199910)29:10<3245::aid-immu3245>3.0.co;2-x · Cited by 365
Vaccinia Virus Inhibits the Maturation of Human Dendritic Cells: A Novel Mechanism of Immune Evasion
Engelmayer, J., Larsson, M., Subklewe, M., Chahroudi, A., Cox, W. I., Steinman, R. M., & Bhardwaj, N. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.12.6762 · Cited by 365
Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes
Tsavaris, N., Kosmas, C., Vadiaka, M., Kanelopoulos, P., & Boulamatsis, D. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600347 · Cited by 343
Casazza, J. P., Betts, M. R., Price, D. A., Precopio, M. L., Ruff, L. E., Brenchley, J. M., Hill, B. J., Roederer, M., Douek, D. C., & Koup, R. A. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052246 · Cited by 337
Kenter, G. G., Welters, M. J. P., Valentijn, A. R. P. M., Löwik, M. J. G., Berends-van der Meer, D. M. A., Vloon, A. P. G., Drijfhout, J. W., Wafelman, A. R., Oostendorp, J., Fleuren, G. J., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1881 · Cited by 315
Tarhini, A. A., Edington, H., Butterfield, L. H., Lin, Y., Shuai, Y., Tawbi, H., Sander, C., Yin, Y., Holtzman, M., Johnson, J., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087705 · Cited by 310
Self-citationA comparison of gene transfer methods in human dendritic cells.
Arthur, J. F., Butterfield, L. H., Roth, M. D., Bùi, L. A., Kiertscher, S. M., Lau, R., Dubinett, S., Glaspy, J. A., McBride, W. H., & Economou, J. S. (1997) · PubMed · Cited by 305
Self-citationSlingluff, C. L. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e318233e5b2 · Cited by 299
Keilholz, U., Weber, J., Finke, J. H., Gabrilovich, D. I., Kast, W. M., Disis, M. L., Kirkwood, J. M., Scheibenbogen, C., Schlom, J., Maino, V. C., et al. (2002) · Journal of Immunotherapy · doi:10.1097/00002371-200203000-00001 · Cited by 298
Gulley, J. L., Arlen, P. M., Madan, R. A., Tsang, K.-Y., Pazdur, M. P., Skarupa, L., Jones, J. L., Poole, D. J., Higgins, J. P., Hodge, J. W., et al. (2010) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-009-0782-8 · Cited by 297
Vitiligo in patients with metastatic melanoma: A good prognostic sign
Nordlund, J. J., Kirkwood, J. M., Forget, B. M., Milton, G., Albert, D. M., & Lerner, A. B. (1983) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(83)70182-9 · Cited by 288
Topalian, S. L., Rivoltini, L., Mancini, M., Markus, N. R., Robbins, P. F., Kawakami, Y., & Rosenberg, S. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.20.9461 · Cited by 286
Mizukoshi, E., Yamashita, T., Arai, K., Sunagozaka, H., Ueda, T., Arihara, F., Kagaya, T., Yamashita, T., Fushimi, K., & Kaneko, S. (2013) · Hepatology · doi:10.1002/hep.26153 · Cited by 273
Trial watch: Chemotherapy with immunogenic cell death inducers
Vacchelli, E., Senovilla, L., Eggermont, A., Fridman, W. H., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.23510 · Cited by 265
Zerbini, A., Pilli, M., Penna, A., Pelosi, G., Schianchi, C., Molinari, A., Schivazappa, S., Zibera, C., Fagnoni, F. F., Ferrari, C., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2244 · Cited by 264
Kimura, T., McKolanis, J. R., Dzubinski, L. A., Islam, K., Potter, D. M., Salazar, A. M., Schoen, R. E., & Finn, O. J. (2013) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-12-0275 · Cited by 263
Weide, B., Martens, A., Zelba, H., Stutz, C., Derhovanessian, E., Di Giacomo, A. M., Maio, M., Sucker, A., Schilling, B., Schadendorf, D., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2508 · Cited by 261
MUC‐1 Epithelial Tumor Mucin‐Based Immunity and Cancer Vaccines
Finn, O. J., Jerome, K. R., Henderson, R. A., Pecher, G., Domenech, N., Magarian‐Blander, J., & Barratt‐Boyes, S. M. (1995) · Immunological Reviews · doi:10.1111/j.1600-065x.1995.tb00077.x · Cited by 261
Dancey, J. E., Dobbin, K. K., Groshen, S., Jessup, J. M., Hruszkewycz, A. H., Koehler, M., Parchment, R., Ratain, M. J., Shankar, L. K., Stadler, W. M., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2167 · Cited by 258
Butterfield, L. H., Ribas, A., Dissette, V. B., Amarnani, S. N., Vu, H. T., Oseguera, D. K., Wang, H.-J., Elashoff, R. M., McBride, W. H., Mukherji, B., et al. (2003) · PubMed · Cited by 255
Self-citationTrial watch: Dendritic cell-based interventions for cancer therapy
Vacchelli, E., Vitale, I., Eggermont, A., Fridman, W. H., Fučíková, J., Cremer, I., Galon, J., Tartour, E., Zitvogel, L., Kroemer, G., et al. (2013) · OncoImmunology · doi:10.4161/onci.25771 · Cited by 247
Nemunaitis, J., Sterman, D., Jablons, D., Smith, J. W., Fox, B., Maples, P., Hamilton, S., Borellini, F., Lin, A., Morali, S., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh028 · Cited by 244
Welters, M. J. P., Kenter, G. G., de Vos van Steenwijk, P. J., Löwik, M. J. G., Berends-van der Meer, D. M. A., Essahsah, F., Stynenbosch, L. F. M., Vloon, A. P. G., Ramwadhdoebe, T. H., Piersma, S. J., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006500107 · Cited by 239
Tumors Promote Altered Maturation and Early Apoptosis of Monocyte-Derived Dendritic Cells
Kiertscher, S. M., Luo, J., Dubinett, S. M., & Roth, M. D. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.3.1269 · Cited by 237
Wierecky, J., Müller, M. R., Wirths, S., Halder-Oehler, E., Dörfel, D., Schmidt, S. M., Häntschel, M., Brugger, W., Schröder, S., Horger, M. S., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3905 · Cited by 228
Rosalia, R. A., Quakkelaar, E. D., Redeker, A., Khan, S., Camps, M., Drijfhout, J. W., Silva, A. L., Jiskoot, W., van Hall, T., van Veelen, P. A., et al. (2013) · European Journal of Immunology · doi:10.1002/eji.201343324 · Cited by 215
Kaufman, H. L., & Bines, S. D. (2010) · Future Oncology · doi:10.2217/fon.10.66 · Cited by 209
Pollack, I. F., Jakacki, R. I., Butterfield, L. H., Hamilton, R. L., Panigrahy, A., Potter, D. M., Connelly, A. K., Dibridge, S. A., Whiteside, T. L., & Okada, H. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.0526 · Cited by 208
Self-citationJanetzki, S., Panageas, K. S., Ben-Porat, L., Boyer, J., Britten, C. M., Clay, T. M., Kalos, M., Maecker, H. T., Romero, P., Yuan, J., et al. (2008) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-007-0380-6 · Cited by 206
Rosenblatt, J., Avivi, I., Vasir, B., Uhl, L., Munshi, N. C., Katz, T., Dey, B. R., Somaiya, P., Mills, H., Campigotto, F., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0282 · Cited by 206
“MIATA”—Minimal Information about T Cell Assays
Janetzki, S., Britten, C. M., Kalos, M., Levitsky, H. I., Maecker, H. T., Melief, C. J. M., Old, L. J., Romero, P., Hoos, A., & Davis, M. M. (2009) · Immunity · doi:10.1016/j.immuni.2009.09.007 · Cited by 190
Radiofrequency Thermal Ablation for Hepatocellular Carcinoma Stimulates Autologous NK-Cell Response
Zerbini, A., Pilli, M., Laccabue, D., Pelosi, G., Molinari, A., Negri, E., Cerioni, S., Fagnoni, F., Soliani, P., Ferrari, C., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.051 · Cited by 188
Mincheff, M., Tchakarov, S., Zoubak, S., Loukinov, D., Botev, C., Altankova, I., Georgiev, G., Petrov, S., & Meryman, H. T. (2000) · European Urology · doi:10.1159/000020281 · Cited by 183
Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein
Disis, M. L., Gralow, J. R., Bernhard, H., Hand, S. L., Rubin, W. D., & Cheever, M. A. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.9.3151 · Cited by 179
Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
Kanerva, A., Nokisalmi, P., Diaconu, I., Koski, A., Cerullo, V., Liikanen, I., Tähtinen, S., Oksanen, M., Heiskanen, R., Pesonen, S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2546 · Cited by 177
Trial Watch: Chemotherapy with immunogenic cell death inducers
Vacchelli, E., Aranda, F., Eggermont, A. M. M., Galon, J., Sautès‐Fridman, C., Cremer, I., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/onci.27878 · Cited by 173
Trial watch: Peptide vaccines in cancer therapy
Vacchelli, E., Martins, I., Eggermont, A., Fridman, W. H., Galon, J., Sautès-Fridman, C., Tartour, E., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2012) · OncoImmunology · doi:10.4161/onci.22428 · Cited by 171
Ayaru, L., Pereira, S. P., Alisa, A., Pathan, A. A., Williams, R., Davidson, B., Burroughs, A. K., Meyer, T., & Behboudi, S. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.3.1914 · Cited by 162
Palucka, K., Ueno, H., Fay, J., & Banchereau, J. (2011) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2010.02317.x · Cited by 162
Bakker, A. B. H., Marland, G., de Boer, A. J., Huijbens, R. J. F., Danen, E. H. J., Adema, G. J., & Figdor, C. G. (1995) · PubMed · Cited by 161
Functional expression of chimeric receptor genes in human T cells
Eshhar, Z., Waks, T., Bendavid, A., & Schindler, D. G. (2001) · Journal of Immunological Methods · doi:10.1016/s0022-1759(00)00343-4 · Cited by 158
Conry, R. M., Curiel, D. T., Strong, T. V., Moore, S. E., Allen, K. O., Barlow, D. L., Shaw, D. R., & LoBuglio, A. F. (2002) · PubMed · Cited by 147
Alpha-fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma.
Vollmer, C. M., Eilber, F. C., Butterfield, L. H., Ribas, A., Dissette, V. B., Koh, A. Y., Montejo, L. D., Lee, M. C., Andrews, K. J., McBride, W. H., et al. (1999) · PubMed · Cited by 142
Self-citationReview: Gene-Modified Dendritic Cells for Use in Tumor Vaccines
Kirk, C. J., & Mulé, J. J. (2000) · Human Gene Therapy · doi:10.1089/10430340050015419 · Cited by 140
Kirkwood, J. M., Lee, S., Moschos, S. J., Albertini, M. R., Michalak, J. C., Sander, C., Whiteside, T. L., Butterfield, L. H., & Weiner, L. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1231 · Cited by 138
Self-citationDendritic Cells in Cancer Immunotherapy Clinical Trials: Are We Making Progress?
Butterfield, L. H. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00454 · Cited by 135
Self-citationSlingluff, C. L., Petroni, G. R., Chianese‐Bullock, K. A., Smolkin, M. E., Ross, M. I., Haas, N. B., von Mehren, M., & Grosh, W. W. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.8053 · Cited by 132
Guo, Z. S., Naik, A. M., O’Malley, M. E., Popovič, P., DeMarco, R., Hu, Y., Yin, X., Yang, S., Zeh, H. J., Moss, B., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1630 · Cited by 126
Slingluff, C. L., Lee, S., Zhao, F., Chianese‐Bullock, K. A., Olson, W. C., Butterfield, L. H., Whiteside, T. L., Leming, P. D., & Kirkwood, J. M. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0002 · Cited by 126
Self-citationAdenovirus MART-1–engineered Autologous Dendritic Cell Vaccine for Metastatic Melanoma
Butterfield, L. H., Comin-Anduix, B., Vujanovic, L. N., Lee, Y., Dissette, V. B., Yang, J.-Q., Vu, H. T., Seja, E., Oseguera, D. K., Potter, D. M., et al. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31816a8910 · Cited by 121
Self-citationImmunologic biomarkers as correlates of clinical response to cancer immunotherapy
Disis, M. L. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0960-8 · Cited by 120
Ribas, A., Glaspy, J. A., Lee, Y., Dissette, V. B., Seja, E., Vu, H. T., Tchekmedyian, N. S., Oseguera, D. K., Comin-Anduix, B., Wargo, J. A., et al. (2004) · Journal of Immunotherapy · doi:10.1097/00002371-200409000-00004 · Cited by 120
Self-citationTrial Watch: Peptide vaccines in cancer therapy
Aranda, F., Vacchelli, E., Eggermont, A. M. M., Galon, J., Sautès‐Fridman, C., Tartour, É., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.26621 · Cited by 119
Fourcade, J. J., Kudela, P., Filho, P. A. A., Janjic, B. M., Land, S. R., Sander, C., Krieg, A. Μ., Donnenberg, A. D., Shen, H., Kirkwood, J. M., et al. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318183af0b · Cited by 117
Determinant spreading and tumor responses after peptide-based cancer immunotherapy
Ribas, A., Timmerman, J. M., Butterfield, L. H., & Economou, J. S. (2003) · Trends in Immunology · doi:10.1016/s1471-4906(02)00029-7 · Cited by 114
Self-citationJohn, L. B., Howland, L. J., Flynn, J. K., West, A. C., Devaud, C., Duong, C. P. M., Stewart, T. J., Westwood, J. A., Guo, Z. S., Bartlett, D. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2788 · Cited by 113
Barth, R. J., Fisher, D. A., Wallace, P. K., Channon, J. Y., Noelle, R. J., Gui, J., & Ernstoff, M. S. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2138 · Cited by 113
Rosenberg, S. A., Yang, J. C.-H., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Rogers-Freezer, L. J., et al. (2003) · Human Gene Therapy · doi:10.1089/104303403765255110 · Cited by 109
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers
Butterfield, L. H., Palucka, A. K., Britten, C. M., Dhodapkar, M. V., Håkansson, L., Janetzki, S., Kawakami, Y., Kleen, T. O., Lee, P. P., Maccalli, C., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2234 · Cited by 108
Self-citationLuiten, R. M., Taanman-Kueter, E. W., Mooi, W. J., Gallee, M. P. W., Rankin, E. M., Gerritsen, W. R., Clift, S., Nooijen, W. J., Weder, P., van de Kasteele, W., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.6816 · Cited by 107
Treatment of solid tumours in children with tumour-lysate-pulsed dendritic cells
Geiger, J. D., Hutchinson, R. J., Hohenkirk, L., McKenna, E., Chang, A. E., & Mulé, J. J. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02762-8 · Cited by 103
Nagato, T., Lee, Y.-R., Harabuchi, Y., & Celis, E. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2781 · Cited by 103
Trial Watch: Anticancer radioimmunotherapy
Vacchelli, E., Vitale, I., Tartour, É., Eggermont, A. M. M., Sautès‐Fridman, C., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.25595 · Cited by 100
Meng, W. S., Butterfield, L. H., Ribas, A., Dissette, V. B., Heller, J. B., Miranda, G. A., Glaspy, J. A., McBride, W. H., & Economou, J. S. (2001) · PubMed · Cited by 99
Self-citationDemaria, S., Pilones, K. A., Vanpouille‐Box, C., Golden, E. B., & Formenti, S. C. (2014) · Radiation Research · doi:10.1667/rr13500.1 · Cited by 95
Clinical Evaluation of TRICOM Vector Therapeutic Cancer Vaccines
Madan, R. A., Bilušić, M., Heery, C. R., Schlom, J., & Gulley, J. L. (2012) · Seminars in Oncology · doi:10.1053/j.seminoncol.2012.02.010 · Cited by 89
Tani, K., Azuma, M., Nakazaki, Y., Oyaizu, N., Hase, H., Ohata, J., TAKAHASHI, K. G., Oiwa‐Monna, M., Hanazawa, K., Wakumoto, Y., et al. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.07.001 · Cited by 86
Diaz, C. M., Chiappori, A., Aurisicchio, L., Bagchi, A., Clark, J., Dubey, S. A., Fridman, A., Fabregas, J. C., Marshall, J. L., Scarselli, E., et al. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-62 · Cited by 80
Disis, M. L., Gad, E. A., Herendeen, D. R., Phan-Lai, V., Park, K. H., Cecil, D. L., O'Meara, M. M., Treuting, P. M., & Lubet, R. A. (2013) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-13-0182 · Cited by 72
Huang, X., Yuan, F., Liang, M., Lo, H., Shinohara, M. L., Robertson, C. N., & Zhong, P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041632 · Cited by 67
for the HLA-peptide Multimer Proficiency Panel of the CVC-CRI Immune Assay Working Group, Britten, C. M., Janetzki, S., Ben‐Porat, L., Clay, T. M., Kalos, M. D., Maecker, H. T., Odunsi, K. O., Pride, M. W., Old, L. J., et al. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-009-0681-z · Cited by 67
A carcinoembryonic antigen polynucleotide vaccine for human clinical use.
Conry, R. M., LoBuglio, A. F., Loechel, F., Moore, S. E., Sumerel, L. A., Barlow, D. L., Pike, J., & Curiel, D. T. (1995) · PubMed · Cited by 67
Cotter, S. E., Dunn, G. P., Collins, K. M., Sahni, D., Zukotynski, K., Hansen, J. L., O’Farrell, D. A., Ng, A. K., Devlin, P. M., & Wang, L. C. (2011) · Archives of Dermatology · doi:10.1001/archdermatol.2011.176 · Cited by 66
Chakraborty, N. G., Sporn, J., Tortora, A. F., Kurtzman, S. H., Yamase, H., Ergin, M. T., & Mukherji, B. (1998) · Cancer Immunology Immunotherapy · doi:10.1007/s002620050504 · Cited by 66
Overwijk, W. W., Wang, E., Marincola, F. M., Rammensee, H., & Restifo, N. P. (2013) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-1-11 · Cited by 65
Li, J., O’Malley, M. E., Sampath, P., Kaliński, P., Bartlett, D. L., & Thorne, S. H. (2012) · Neoplasia · doi:10.1593/neo.121272 · Cited by 64
Clinical Development of Listeria monocytogenes–Based Immunotherapies
Le, D. T., Dubensky, T. W., & Brockstedt, D. G. (2012) · Seminars in Oncology · doi:10.1053/j.seminoncol.2012.02.008 · Cited by 63
Tarhini, A. A., Butterfield, L. H., Shuai, Y., Gooding, W. E., Kaliński, P., & Kirkwood, J. M. (2012) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318272569b · Cited by 62
Self-citationSchumacher, L., Ribas, A., Dissette, V. B., McBride, W. H., Mukherji, B., Economou, J. S., & Butterfield, L. H. (2004) · Journal of Immunotherapy · doi:10.1097/00002371-200405000-00003 · Cited by 60
Self-citationImmunotherapy at Large: The road to personalized cancer vaccines
Vonderheide, R. H., & Nathanson, K. L. (2013) · Nature Medicine · doi:10.1038/nm.3317 · Cited by 54
The Impact of Harmonization on ELISPOT Assay Performance
Janetzki, S., & Britten, C. M. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-325-7_2 · Cited by 39
Schaefer, C., Butterfield, L. H., Lee, S., Kim, G. G., Visús, C., Albers, A. E., Kirkwood, J. M., & Whiteside, T. L. (2011) · International Journal of Cancer · doi:10.1002/ijc.26481 · Cited by 39
Self-citationCD8+ T-Cell Responses against Hemoglobin-β Prevent Solid Tumor Growth
Komita, H., Zhao, X., Taylor, J. L., Sparvero, L. J., Amoscato, A. A., Alber, S. M., Watkins, S. C., Pardee, A. D., Wesa, A. K., & Storkus, W. J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0387 · Cited by 37
Current Experience With CTLA4-blocking Monoclonal Antibodies for the Treatment of Solid Tumors
Agarwala, S. S., & Ribas, A. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181dcd260 · Cited by 36
Hu, Y., Petroni, G. R., Olson, W. C., Czarkowski, A. R., Smolkin, M. E., Grosh, W. W., Chianese‐Bullock, K. A., & Slingluff, C. L. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1551-x · Cited by 33
Of mice and men: what rodent models don't tell us
Drake, A. C. B. (2013) · Cellular and Molecular Immunology · doi:10.1038/cmi.2013.21 · Cited by 30
Townsend, K. N., Spowart, J. E., Huwait, H., Eshragh, S., West, N. R., Elrick, M. A., Kalloger, S. E., Anglesio, M., Watson, P. H., Huntsman, D. G., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082406 · Cited by 29
Rosenberg, S. A., Yang, J. C.-H., Kammula, U. S., Hughes, M. S., Restifo, N. P., Schwarz, S. L., Morton, K. E., Laurençot, C. M., & Sherry, R. M. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181dac9de · Cited by 27
Cytotoxic effects of crystal proteins from Bacillus thuringiensis against breast cancer cells.
Tharakan, B., Devaki, G., Nair, H., & Padikkala, J. (2009) · Cancer Research · doi:10.1158/0008-5472.sabcs-3077 · Cited by 26
Correspondence 2: Cancer vaccines: pessimism in check
Timmerman, J. M., & Levy, R. (2004) · Nature Medicine · doi:10.1038/nm1204-1279a · Cited by 23
Ultrasound-based combination therapy: potential in urologic cancer
Finley, D. S., Pouliot, F., Shuch, B. M., Chin, A. I., Pantuck, A. J., deKernion, J. B., & Belldegrun, A. S. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.174 · Cited by 19
Activation of antigen-presenting cells by DNA delivery vectors
Meng, W. S., & Butterfield, L. H. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.5.8.1019 · Cited by 17
Self-citationMouse Models of Kras-Mutant Colorectal Cancer: Valuable GEMMs for Drug Testing?
Nicolantonio, F. D., & Bardelli, A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0339 · Cited by 3
Cited by
Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
Chen, L., & Han, X. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80011 · Cited by 1,437
Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy
Oberli, M. A., Reichmuth, A. M., Dorkin, J. R., Mitchell, M. J., Fenton, O. S., Jaklenec, A., Anderson, D. G., Langer, R., & Blankschtein, D. (2017) · Nano Letters · doi:10.1021/acs.nanolett.6b03329 · Cited by 719
Neoantigen vaccine: an emerging tumor immunotherapy
Peng, M., Mo, Y., Wang, Y., Wu, P., Zhang, Y., Xiong, F., Guo, C., Wu, X., Li, Y., Li, X., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1055-6 · Cited by 700
Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy
Durgeau, A., Virk, Y., Corgnac, S., & Mami-Chouaib, F. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00014 · Cited by 495
Cancer immunotherapies: advances and bottlenecks
Rui, R., Zhou, L., & He, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1212476 · Cited by 484
Metadata
- Authors
- Butterfield, L. H.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2015-04-22
- Volume
- 350
- Issue
- apr22 14
- Pages
- h988-h988
- ISSN
- 1756-1833 (ISSN-L)
- OpenAlex
- W2416880410
- Cited by
- 272
- References
- 143
- FWCI
- 10.44
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.